ClinicalTrials.gg
CompletedNCT02320149Updated Feb 15, 2019Results posted

Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne

A Phase 3 interventional study of Sarecycline and Placebo in Acne Vulgaris, sponsored by Almirall, S.A.. Completed at 57 sites in United States. Open to participants aged 9 Years to 45 Years. Per ClinicalTrials.gov, last updated 2019-02-15.

Sponsored by Almirall, S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
968
Allocation
Randomized
Ages
9 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 373 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.

Enrollment
31st of 353
968 · median 78
Started
2014
with 16 others
Phase 3
76 of 373
1 open now
Registered
159th of 373
by date
Lead sponsor
8 of 373
Almirall, S.A.

Among the 373 studies in Acne Vulgaris with a site in United States, this one is the 31st largest by enrollment of the 353 interventional ones that give a count, is one of 17 that started in 2014, is one of 76 in phase 3, and was the 159th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

20 of the 373 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 9 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 373 studies in Acne Vulgaris with a site in United States, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of an approximate 1.5mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • acne
04

Who can participate

Ages eligible
9 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed or assent form
  • Male/female, 9 to 45 years of age, inclusive
  • Body weight between 33 and 136 kg, inclusive
  • Facial acne vulgaris with:
  • 20-50 inflammatory lesions (papules, pustules and nodules) 30-100 noninflammatory lesions (open and closed comedones)
  • No more than 2 nodules
  • IGA score of moderate (3) or severe (4)
  • Negative urine pregnancy test at baseline - females of
  • Agrees to use an effective method of throughout the study
  • Refrain from use of any other acne medications and medicated cleansers, and avoid excessive sun exposure and tanning booths for duration of study
  • Able to fulfill the requirements of protocol, indicated willingness to participate in the study and agrees to all study procedures (including mandatory photography) by providing written informed consent/assent and an authorization to disclose protected health information (PHI)

Exclusion criteria

Exclusion Criteria:

  • Has a dermatological condition of the face that could interfere with the clinical evaluations
  • Has a history of any of the following:
  • Allergy to tetracycline-class antibiotics or to any ingredient in the study drug
  • Pseudomembranous colitis or antibiotic associated colitis
  • Treated for any type of cancer within the last 6 months
  • Has known resistance to other tetracyclines
  • Has received any of the following treatments within 12 weeks of screening:
  • Systemic retinoids
  • Systemic
  • Androgens/anti-androgenic therapy (eg, anabolic steroids, spironolactone)
  • Non-medicated procedures for the treatment of acne (eg, laser, light or ThermaClear)
  • Has used any acne affecting treatment without an appropriate
  • Has initiated hormonal use within 12 weeks prior to screening or plans to initiate or switch hormonal contraceptive products during the study period
  • Is pregnant, lactating or planning a pregnancy during the study period
  • Has any other disorder causing hyperandrogenism including, but not limited to polycystic ovary syndrome, adrenal or ovarian tumors, Cushings disease or congenital adrenal hyperplasia
  • Has drug-induced acne
  • Has significant intercurrent illness, psychiatric disposition or other factors that, in the opinion of the Investigator or Medical Monitor, precludes participation in the study
  • Is currently participating, or has participated within 30 days prior to the screening period in an drug or device study
  • Has previously participated in any clinical trial involving the use of sarecycline
  • Is judged by the Investigator to be unsuitable for any reason
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
968 participants (actual)

Study arms

  • Experimental
    Sarecycline

    Sarecycline tablets, 1.5 milligram(mg)/kilogram(kg)/day, taken orally once daily for 12 weeks.

    Drug: Sarecycline

  • Placebo comparator
    Placebo

    Placebo-matching sarecycline tablets, taken orally once daily for 12 weeks.

    Drug: Placebo

Interventions

  • 1.5 mg/kg/day taken orally at the same time each day,

  • DrugPlacebo

    Placebo-matching sarecycline tablets taken orally at the same time each day.

06

What researchers measure

Primary outcomes

  1. Absolute Change in Facial Inflammatory Lesion Counts at Week 12

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 centimeter (cm) in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on Analysis of Covariance (ANCOVA) model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 12

  2. Percentage of Participants With Investigator Global Assement (IGA) Success at Week 12

    The investigator assessed the participant's inflammatory lesions on the face using the IGA 5-point scale. The scale ranges from 0 (best): clear, no evidence of papules or pustules to 4 (worst): severe, inflammatory lesions are more apparent, many papules/pustules, there may or may not be a few nodulocytic lesions. Success was defined as at least a 2-point decrease (improvement) from Baseline on the IGA assessment as well as a score of clear (0) or almost clear (1). The percentage of participants who achieved success is reported.

    Time frame: Baseline (Day 1) to Week 12

Secondary outcomes

  1. Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 12

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 centimeter (cm) in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 12

  2. Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 9

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 centimeter (cm) in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 9

  3. Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 6

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 centimeter (cm) in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 6

  4. Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 3

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 centimeter (cm) in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 3

  5. Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 9

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 9

  6. Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 6

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Weeks 6

  7. Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 3

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 3

  8. Percent Change From Baseline in Facial Noninflammatory Lesion Counts at Week 12

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Noninflammatory lesion counts were based on the following definitions: open comedones (blackheads): noninfected plugged hair follicle with a dilated/open orifice, black in color; closed comedones (whiteheads): noninfected plugged hair follicle with a small (microscopic) opening at the surface of the skin. A negative change from Baseline indicates that the number of noninflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 12

  9. Percent Change From Baseline in Facial Noninflammatory Lesion Counts at Week 9

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Noninflammatory lesion counts were based on the following definitions: open comedones (blackheads): noninfected plugged hair follicle with a dilated/open orifice, black in color; closed comedones (whiteheads): noninfected plugged hair follicle with a small (microscopic) opening at the surface of the skin. A negative change from Baseline indicates that the number of noninflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 9

  10. Percent Change From Baseline in Facial Noninflammatory Lesion Counts at Week 6

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Noninflammatory lesion counts were based on the following definitions: open comedones (blackheads): noninfected plugged hair follicle with a dilated/open orifice, black in color; closed comedones (whiteheads): noninfected plugged hair follicle with a small (microscopic) opening at the surface of the skin. A negative change from Baseline indicates that the number of noninflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 6

  11. Percent Change From Baseline in Facial Noninflammatory Lesion Counts at Week 3

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Noninflammatory lesion counts were based on the following definitions: open comedones (blackheads): noninfected plugged hair follicle with a dilated/open orifice, black in color; closed comedones (whiteheads): noninfected plugged hair follicle with a small (microscopic) opening at the surface of the skin. A negative change from Baseline indicates that the number of noninflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 3

  12. Absolute Change From Baseline in Facial Noninflammatory Lesion Counts at Week 12

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Noninflammatory lesion counts were based on the following definitions: open comedones (blackheads): noninfected plugged hair follicle with a dilated/open orifice, black in color; closed comedones (whiteheads): noninfected plugged hair follicle with a small (microscopic) opening at the surface of the skin. A negative change from Baseline indicates that the number of noninflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 12

  13. Absolute Change From Baseline in Facial Noninflammatory Lesion Counts at Week 9

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Noninflammatory lesion counts were based on the following definitions: open comedones (blackheads): noninfected plugged hair follicle with a dilated/open orifice, black in color; closed comedones (whiteheads): noninfected plugged hair follicle with a small (microscopic) opening at the surface of the skin. A negative change from Baseline indicates that the number of noninflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 9

  14. Absolute Change From Baseline in Facial Noninflammatory Lesion Counts at Week 6

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Noninflammatory lesion counts were based on the following definitions: open comedones (blackheads): noninfected plugged hair follicle with a dilated/open orifice, black in color; closed comedones (whiteheads): noninfected plugged hair follicle with a small (microscopic) opening at the surface of the skin. A negative change from Baseline indicates that the number of noninflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 6

  15. Absolute Change From Baseline in Facial Noninflammatory Lesion Counts at Week 3

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Noninflammatory lesion counts were based on the following definitions: open comedones (blackheads): noninfected plugged hair follicle with a dilated/open orifice, black in color; closed comedones (whiteheads): noninfected plugged hair follicle with a small (microscopic) opening at the surface of the skin. A negative change from Baseline indicates that the number of noninflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 3

07

Results

Posted May 17, 2018

Participant flow

Participant flow — Overall Study
MilestoneSarecyclinePlacebo
Started483485
Completed420405
Not completed6380
Withdrew: Adverse event37
Withdrew: Withdrawal of consent2832
Withdrew: Lost to follow-up2134
Withdrew: Protocol violation21
Withdrew: Noncompliance with study treatment72
Withdrew: Lack of efficacy01
Withdrew: Other miscellaneous reasons23

Outcome measures

PrimaryAbsolute Change in Facial Inflammatory Lesion Counts at Week 12

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 centimeter (cm) in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on Analysis of Covariance (ANCOVA) model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Least squares mean · lesion count
Absolute Change in Facial Inflammatory Lesion Counts at Week 12
lesion countSarecyclinePlacebo
Absolute Change in Facial Inflammatory Lesion Counts at Week 12-15.3 ± 0.6-10.1 ± 0.6
Statistical analysis
  • Sarecycline vs Placebo · ANCOVA · p = < 0.0001 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -5.2 · 95% CI -6.7 to -3.6sarecycline - placebo
PrimaryPercentage of Participants With Investigator Global Assement (IGA) Success at Week 12

The investigator assessed the participant's inflammatory lesions on the face using the IGA 5-point scale. The scale ranges from 0 (best): clear, no evidence of papules or pustules to 4 (worst): severe, inflammatory lesions are more apparent, many papules/pustules, there may or may not be a few nodulocytic lesions. Success was defined as at least a 2-point decrease (improvement) from Baseline on the IGA assessment as well as a score of clear (0) or almost clear (1). The percentage of participants who achieved success is reported.

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Investigator Global Assement (IGA) Success at Week 12
percentage of participantsSarecyclinePlacebo
Percentage of Participants With Investigator Global Assement (IGA) Success at Week 1221.910.5
Statistical analysis
  • Sarecycline vs Placebo · Cochran-Mantel-Haenszel · p = < 0.0001 (P-values were based on the test of general association between the response and treatment group using Cochran-Mantel-Haenszel test with pooled site as stratification factor.) · Treatment rate difference: 11.05 · 95% CI 6.39 to 15.72sarecycline - placebo
SecondaryPercent Change From Baseline in Facial Inflammatory Lesion Counts at Week 12

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 centimeter (cm) in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Least squares mean · percent change in lesion count
Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 12
percent change in lesion countSarecyclinePlacebo
Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 12-51.8 ± 1.9-35.1 ± 2.0
Statistical analysis
  • Sarecycline vs Placebo · ANCOVA · p = < 0.0001 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -16.7 · 95% CI -21.9 to -11.6sarecycline - placebo
SecondaryPercent Change From Baseline in Facial Inflammatory Lesion Counts at Week 9

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 centimeter (cm) in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 9
Reported as:
Least squares mean · percent change in lesion count
Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 9
percent change in lesion countSarecyclinePlacebo
Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 9-47.4 ± 1.7-34.9 ± 1.7
Statistical analysis
  • Sarecycline vs Placebo · ANCOVA · p = < 0.0001 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -12.5 · 95% CI -16.9 to -8.0sarecycline - placebo
SecondaryPercent Change From Baseline in Facial Inflammatory Lesion Counts at Week 6

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 centimeter (cm) in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 6
Reported as:
Least squares mean · percent change in lesion count
Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 6
percent change in lesion countSarecyclinePlacebo
Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 6-42.2 ± 1.6-28.9 ± 1.6
Statistical analysis
  • Sarecycline vs Placebo · ANCOVA · p = < 0.0001 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -13.3 · 95% CI -17.5 to -9.1sarecycline - placebo
SecondaryPercent Change From Baseline in Facial Inflammatory Lesion Counts at Week 3

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 centimeter (cm) in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 3
Reported as:
Least squares mean · percent change in lesion count
Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 3
percent change in lesion countSarecyclinePlacebo
Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 3-29.6 ± 1.5-22.4 ± 1.5
Statistical analysis
  • Sarecycline vs Placebo · ANCOVA · p = 0.0003 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -7.2 · 95% CI -11.1 to -3.3sarecycline - placebo
SecondaryAbsolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 9

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 9
Reported as:
Least squares mean · lesion count
Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 9
lesion countSarecyclinePlacebo
Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 9-13.9 ± 0.5-10.0 ± 0.5
Statistical analysis
  • Sarecycline vs Placebo · ANCOVA · p = < 0.0001 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -3.9 · 95% CI -5.3 to -2.5sarecycline - placebo
SecondaryAbsolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 6

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Weeks 6
Reported as:
Least squares mean · lesion count
Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 6
lesion countSarecyclinePlacebo
Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 6-12.5 ± 0.5-8.4 ± 0.5
Statistical analysis
  • Sarecycline vs Placebo · ANCOVA · p = < 0.0001 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -4.1 · 95% CI -5.4 to -2.9sarecycline - placebo
SecondaryAbsolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 3

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 3
Reported as:
Least squares mean · lesion count
Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 3
lesion countSarecyclinePlacebo
Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 3-8.5 ± 0.4-6.4 ± 0.4
Statistical analysis
  • Sarecycline vs Placebo · ANCOVA · p = 0.0005 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -2.1 · 95% CI -3.3 to -0.9sarecycline - placebo
SecondaryPercent Change From Baseline in Facial Noninflammatory Lesion Counts at Week 12

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Noninflammatory lesion counts were based on the following definitions: open comedones (blackheads): noninfected plugged hair follicle with a dilated/open orifice, black in color; closed comedones (whiteheads): noninfected plugged hair follicle with a small (microscopic) opening at the surface of the skin. A negative change from Baseline indicates that the number of noninflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Least squares mean · percent change in lesion count
Percent Change From Baseline in Facial Noninflammatory Lesion Counts at Week 12
percent change in lesion countSarecyclinePlacebo
Percent Change From Baseline in Facial Noninflammatory Lesion Counts at Week 12-27.0 ± 5.6-22.7 ± 5.6
Statistical analysis
  • Sarecycline vs Placebo · ANCOVA · p = 0.5786 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -4.3 · 95% CI -19.4 to 10.8sarecycline - placebo
SecondaryPercent Change From Baseline in Facial Noninflammatory Lesion Counts at Week 9

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Noninflammatory lesion counts were based on the following definitions: open comedones (blackheads): noninfected plugged hair follicle with a dilated/open orifice, black in color; closed comedones (whiteheads): noninfected plugged hair follicle with a small (microscopic) opening at the surface of the skin. A negative change from Baseline indicates that the number of noninflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 9
Reported as:
Least squares mean · percent change in lesion count
Percent Change From Baseline in Facial Noninflammatory Lesion Counts at Week 9
percent change in lesion countSarecyclinePlacebo
Percent Change From Baseline in Facial Noninflammatory Lesion Counts at Week 9-20.8 ± 5.3-18.0 ± 5.3
Statistical analysis
  • Sarecycline vs Placebo · ANCOVA · p = 0.6969 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -2.8 · 95% CI -17.1 to 11.4sarecycline - placebo
SecondaryPercent Change From Baseline in Facial Noninflammatory Lesion Counts at Week 6

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Noninflammatory lesion counts were based on the following definitions: open comedones (blackheads): noninfected plugged hair follicle with a dilated/open orifice, black in color; closed comedones (whiteheads): noninfected plugged hair follicle with a small (microscopic) opening at the surface of the skin. A negative change from Baseline indicates that the number of noninflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 6
Reported as:
Least squares mean · percent change in lesion count
Percent Change From Baseline in Facial Noninflammatory Lesion Counts at Week 6
percent change in lesion countSarecyclinePlacebo
Percent Change From Baseline in Facial Noninflammatory Lesion Counts at Week 6-14.6 ± 6.6-17.6 ± 6.6
Statistical analysis
  • Sarecycline vs Placebo · ANCOVA · p = 0.7377 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: 3.0 · 95% CI -14.7 to 20.7sarecycline - placebo
SecondaryPercent Change From Baseline in Facial Noninflammatory Lesion Counts at Week 3

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Noninflammatory lesion counts were based on the following definitions: open comedones (blackheads): noninfected plugged hair follicle with a dilated/open orifice, black in color; closed comedones (whiteheads): noninfected plugged hair follicle with a small (microscopic) opening at the surface of the skin. A negative change from Baseline indicates that the number of noninflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 3
Reported as:
Least squares mean · percent change in lesion count
Percent Change From Baseline in Facial Noninflammatory Lesion Counts at Week 3
percent change in lesion countSarecyclinePlacebo
Percent Change From Baseline in Facial Noninflammatory Lesion Counts at Week 3-8.0 ± 4.4-14.3 ± 4.3
Statistical analysis
  • Sarecycline vs Placebo · ANCOVA · p = 0.2861 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: 6.4 · 95% CI -5.3 to 18.1sarecycline - placebo
SecondaryAbsolute Change From Baseline in Facial Noninflammatory Lesion Counts at Week 12

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Noninflammatory lesion counts were based on the following definitions: open comedones (blackheads): noninfected plugged hair follicle with a dilated/open orifice, black in color; closed comedones (whiteheads): noninfected plugged hair follicle with a small (microscopic) opening at the surface of the skin. A negative change from Baseline indicates that the number of noninflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Least squares mean · lesion count
Absolute Change From Baseline in Facial Noninflammatory Lesion Counts at Week 12
lesion countSarecyclinePlacebo
Absolute Change From Baseline in Facial Noninflammatory Lesion Counts at Week 12-15.1 ± 0.9-11.2 ± 0.9
Statistical analysis
  • Sarecycline vs Placebo · ANCOVA · p = 0.0014 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -3.9 · 95% CI -6.3 to -1.5sarecycline - placebo
SecondaryAbsolute Change From Baseline in Facial Noninflammatory Lesion Counts at Week 9

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Noninflammatory lesion counts were based on the following definitions: open comedones (blackheads): noninfected plugged hair follicle with a dilated/open orifice, black in color; closed comedones (whiteheads): noninfected plugged hair follicle with a small (microscopic) opening at the surface of the skin. A negative change from Baseline indicates that the number of noninflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 9
Reported as:
Least squares mean · lesion count
Absolute Change From Baseline in Facial Noninflammatory Lesion Counts at Week 9
lesion countSarecyclinePlacebo
Absolute Change From Baseline in Facial Noninflammatory Lesion Counts at Week 9-13.0 ± 0.8-9.6 ± 0.8
Statistical analysis
  • Sarecycline vs Placebo · ANCOVA · p = 0.0010 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -3.4 · 95% CI -5.5 to -1.4sarecycline - placebo
SecondaryAbsolute Change From Baseline in Facial Noninflammatory Lesion Counts at Week 6

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Noninflammatory lesion counts were based on the following definitions: open comedones (blackheads): noninfected plugged hair follicle with a dilated/open orifice, black in color; closed comedones (whiteheads): noninfected plugged hair follicle with a small (microscopic) opening at the surface of the skin. A negative change from Baseline indicates that the number of noninflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 6
Reported as:
Least squares mean · lesion count
Absolute Change From Baseline in Facial Noninflammatory Lesion Counts at Week 6
lesion countSarecyclinePlacebo
Absolute Change From Baseline in Facial Noninflammatory Lesion Counts at Week 6-10.6 ± 0.7-8.6 ± 0.7
Statistical analysis
  • Sarecycline vs Placebo · ANCOVA · p = 0.0371 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -2.0 · 95% CI -4.0 to -0.1sarecycline - placebo
SecondaryAbsolute Change From Baseline in Facial Noninflammatory Lesion Counts at Week 3

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Noninflammatory lesion counts were based on the following definitions: open comedones (blackheads): noninfected plugged hair follicle with a dilated/open orifice, black in color; closed comedones (whiteheads): noninfected plugged hair follicle with a small (microscopic) opening at the surface of the skin. A negative change from Baseline indicates that the number of noninflammatory lesions decreased. Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 3
Reported as:
Least squares mean · lesion count
Absolute Change From Baseline in Facial Noninflammatory Lesion Counts at Week 3
lesion countSarecyclinePlacebo
Absolute Change From Baseline in Facial Noninflammatory Lesion Counts at Week 3-7.9 ± 0.6-7.1 ± 0.6
Statistical analysis
  • Sarecycline vs Placebo · ANCOVA · p = 0.3806 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -0.8 · 95% CI -2.5 to 1.0sarecycline - placebo

Adverse events

Collected over Up to 20.7 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sarecycline0/481 (0%)3/481 (0.6%)0/481 (0%)
Placebo0/483 (0%)5/483 (1%)0/483 (0%)
Most frequent serious events
Most frequent serious events
EventSarecyclinePlacebo
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/4812/483
Alanine aminotransferase increasedInvestigations1/4810/483
Aspartate aminotransferase increasedInvestigations1/4810/483
Gamma-glutamyltransferase increasedInvestigations1/4810/483
Diabetic ketoacidosisMetabolism and nutrition disorders1/4810/483
NephrolithiasisRenal and urinary disorders1/4810/483
AppendicitisInfections and infestations0/4811/483
CellulitisInfections and infestations0/4811/483
Suicide attemptPsychiatric disorders0/4811/483
Miscarriage of partnerSocial circumstances0/4811/483

Baseline characteristics

Intent-to-treat (ITT) Population included all randomized participants.

Age, Customized
Age, Customized(participants)SarecyclinePlaceboTotal
≥9 and <12 Years4610
≥12 and <18 Years241235476
≥18 Years238244482
Sex: Female, Male
Sex: Female, Male(Participants)SarecyclinePlaceboTotal
Female268271539
Male215214429
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SarecyclinePlaceboTotal
White377377754
Black or African American8079159
Asian11920
American Indian or Alaska Native235
Native Hawaiian or other Pacific Islander235
Multiple races111425
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SarecyclinePlaceboTotal
Hispanic or Latino144143287
Not Hispanic or Latino339342681
Inflammatory Lesion Counts
Inflammatory Lesion Counts(lesion count)SarecyclinePlaceboTotal
Mean29.7 ± 8.730.2 ± 9.630.0 ± 9.2
Investigator's Global Assessment (IGA) Score - Face
Investigator's Global Assessment (IGA) Score - Face(score on a scale)SarecyclinePlaceboTotal
Mean3.1 ± 0.43.2 ± 0.43.1 ± 0.4
08

Study locations

57 sites
  • Warner Chilcott Research Site (Site #155)
    Beverly Hills, California 90210, United States
  • Warner Chilcott Research Site (Site #129)
    Encino, California 91436, United States
  • Warner Chilcott Research Site (Site #150)
    La Mesa, California 91942, United States
  • Warner Chilcott Research Site (Site #136)
    Los Angeles, California 90045, United States
  • Warner Chilcott Research Site (Site #147)
    Sacramento, California 95819, United States
  • Warner Chilcott Research Site (Site #123)
    San Diego, California 92117, United States
  • Warner Chilcott Research Site (Site #125)
    San Diego, California 92123, United States
  • Warner Chilcott Research Site (Site #139)
    Santa Rosa, California 95403, United States
  • Warner Chilcott Research Site (Site #157)
    Tustin, California 92780, United States
  • Warner Chilcott Research Site (Site #122)
    Denver, Colorado 80209, United States
  • Warner Chilcott Research Site (Site #148)
    Wheat Ridge, Colorado 80033, United States
  • Warner Chilcott Research Site (Site #133)
    New Haven, Connecticut 06511, United States
  • Warner Chilcott Research Site (Site #130)
    Boca Raton, Florida 33486, United States
  • Warner Chilcott Research Site (Site #152)
    Boynton Beach, Florida 33437, United States
  • Warner Chilcott Research Site (Site #102)
    Miami, Florida 33025, United States
  • Warner Chilcott Research Site (Site #145)
    Miami, Florida 33175, United States
  • Warner Chilcott Research Site (Site #140)
    North Miami Beach, Florida 33162, United States
  • Warner Chilcott Research Site (Site #151)
    Orange Park, Florida 32073, United States
  • Warner Chilcott Research Site (Site #108)
    Sanford, Florida 32771, United States
  • Warner Chilcott Research Site (Site #110)
    West Palm Beach, Florida 33409, United States
  • Warner Chilcott Research Site (Site #154)
    Atlanta, Georgia 30328, United States
  • Warner Chilcott Research Site (Site #120)
    Augusta, Georgia 30909, United States
  • Warner Chilcott Research Site (Site #124)
    Boise, Idaho 83704, United States
  • Warner Chilcott Research Site (Site #106)
    Chicago, Illinois 60611, United States
  • Warner Chilcott Research Site (Site #112)
    Plainfield, Indiana 46168, United States
  • Warner Chilcott Research Site (Site #113)
    South Bend, Indiana 46617, United States
  • Warner Chilcott Research Site (Site #117)
    Louisville, Kentucky 40217, United States
  • Warner Chilcott Research Site (Site #135)
    Lake Charles, Louisiana 70605, United States
  • Warner Chilcott Research Site (Site #153)
    Metairie, Louisiana 70006, United States
  • Warner Chilcott Research Site (Site #137)
    Detroit, Michigan 48202, United States
  • Warner Chilcott Research Site (Site #111)
    Warren, Michigan 48088, United States
  • Warner Chilcott Research Site (Site #119)
    Saint Louis, Missouri 63117, United States
  • Warner Chilcott Research Site (Site #138)
    Omaha, Nebraska 68114, United States
  • Warner Chilcott Research Site (Site #103)
    Henderson, Nevada 89074, United States
  • Warner Chilcott Research Site (Site #127)
    Verona, New Jersey 07044, United States
  • Warner Chilcott Research Site (Site #146)
    New York, New York 10016, United States
  • Warner Chilcott Research Site (Site #132)
    New York, New York 10075, United States
  • Warner Chilcott Research Site (Site #134)
    Smithtown, New York 11787, United States
  • Warner Chilcott Research Site (Site #107)
    High Point, North Carolina 27262, United States
  • Warner Chilcott Research Site (Site #126)
    Cincinnati, Ohio 45249, United States
  • Warner Chilcott Research Site (Site #143)
    Warren, Ohio 44483, United States
  • Warner Chilcott Research Site (Site #149)
    Gresham, Oregon 97030, United States
  • Warner Chilcott Research Site (Site #131)
    Portland, Oregon 97210, United States
  • Warner Chilcott Research Site (Site #114)
    Greer, South Carolina 29650, United States
  • Warner Chilcott Research Site (Site #128)
    Knoxville, Tennessee 37917, United States
  • Warner Chilcott Research Site (Site #109)
    Nashville, Tennessee 37215, United States
  • Warner Chilcott Research Site (Site #116)
    Austin, Texas 78759, United States
  • Warner Chilcott Research Site (Site #104)
    Dallas, Texas 75234, United States
  • Warner Chilcott Research Site (Site #115)
    El Paso, Texas 79902, United States
  • Warner Chilcott Research Site (Site #142)
    Houston, Texas 77004, United States
  • Warner Chilcott Research Site (Site #105)
    Houston, Texas 77056, United States
  • Warner Chilcott Research Site (Site #101)
    Plano, Texas 75093, United States
  • Warner Chilcott Research Site (Site #118)
    San Antonio, Texas 78229, United States
  • Warner Chilcott Research Site (Site #156)
    Layton, Utah 84041, United States
  • Warner Chilcott Research Site (Site #141)
    Salt Lake City, Utah 84117, United States
  • Warner Chilcott Research Site (Site #121)
    Charlottesville, Virginia 22911, United States
  • Warner Chilcott Research Site (Site #144)
    Spokane, Washington 99204, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Feb 2017, 25 months.

Results were first posted in May 2018, 1 year 3 months after primary completion. A results delay was requested in Feb 2018.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 25 months is above that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2014
First posted
Dec 19, 2014
StartActual
Dec 18, 2014
Primary completionActual
Feb 1, 2017
CompletionActual
Feb 1, 2017
Results delay requested
Feb 2, 2018
Results first posted
May 17, 2018
Last update
Feb 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02320149
Lead sponsor
Almirall, S.A.
Collaborators
Allergan
Responsible party
Sponsor
First posted
Dec 19, 2014
Start date
Dec 18, 2014
Primary completion
Feb 1, 2017
Completion
Feb 1, 2017
Results posted
May 17, 2018
Last update
Feb 15, 2019

Study contacts

Alexandre Kaoukhov, MD
study director · Warner Chilcott, an Affiliate of Allergan plc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sarecycline

Start the discussion